Search Results

You are looking at 1 - 10 of 12 items for :

  • "intravesical chemotherapy" x
Clear All
Full access

Michael R. Abern, Richmond A. Owusu, Mark R. Anderson, Edward N. Rampersaud and Brant A. Inman

initial presentation, 75% to 85% are non–muscle-invasive bladder cancers (NMIBCs), which include stages Ta, T1, and Tis. 2 Several studies have shown a benefit of immediate intravesical chemotherapy (IVC) after transurethral resection (TUR) in reducing

Full access

James E. Montie, Peter E. Clark, Mario A. Eisenberger, Rizk El-Galley, Richard E. Greenberg, Harry W. Herr, Gary R. Hudes, Deborah A. Kuban, Timothy M. Kuzel, Paul H. Lange, Subodh M. Lele, Jeffrey Michalski, Anthony Patterson, Kamal S. Pohar, Jerome P. Richie, Wade J. Sexton, William U. Shipley, Eric J. Small, Donald L. Trump, Phillip J. Walther and Timothy G. Wilson

Hall RR Parmar MK Richards AB Smith PH . Changes in cystoscopic follow up in patients with bladder cancer and adjuvant intravesical chemotherapy . BMJ 1994 ; 308 : 257 – 260 . 5 Greene FL Page DL Fleming ID ., eds. AJCC Cancer Staging

Full access

Thomas W. Flaig, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Sam Chang, Tracy M. Downs, Jason A. Efstathiou, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Thomas Guzzo, Harry W. Herr, Jean Hoffman-Censits, Christopher Hoimes, Brant A. Inman, Masahito Jimbo, A. Karim Kader, Subodh M. Lele, Jeff Michalski, Jeffrey S. Montgomery, Lakshminarayanan Nandagopal, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Mark A. Preston, Wade J. Sexton, Arlene O. Siefker-Radtke, Jonathan Tward, Jonathan L. Wright, Lisa A. Gurski and Alyse Johnson-Chilla

24 hours of TURBT to prevent tumor cell implantation and early recurrence. Immediate intravesical chemotherapy has been shown to decrease recurrence in select subgroups of patients. A systematic review and meta-analysis of 13 randomized trials

Full access

Trump Donald L. MD Wile Geoffrey MD Wilson Timothy G. MD Dwyer Mary MS Ho Maria PhD 04 2013 11 11 4 4 446 446 475 475 0110446 10.6004/jnccn.2013.0059 Perioperative Intravesical Chemotherapy in Non–Muscle-Invasive Bladder

Full access

Presenter : Philippe E. Spiess

significantly better after you've completed a complete resection in terms of recurrence-free and progression-free survival.” In patients with high-grade Ta tumors, BCG is the preferred treatment option after re-resection, followed by intravesical chemotherapy or

Full access

Ellen L. Jones, Lawrence B. Marks and Leonard R. Prosnitz

. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma . J Clin Oncol 2003 ; 21 : 4270 – 4276 . 22. Sugimachi K Kuwano H Ide H

Full access

Jeffrey S. Montgomery, David C. Miller and Alon Z. Weizer

-based neoadjuvant chemotherapy for patients with T2–T4 localized bladder cancer followed by radical cystectomy to optimize disease outcomes. 15 Perioperative Intravesical Chemotherapy Studies dating back to the early 1990s evaluated the use of immediate

Full access

Stephen A. Brassell and Ashish M. Kamat

mitomycin C for high risk superficial bladder cancer: a prospective randomised study . J Urol 2003 ; 170 : 777 – 782 . 64. Gofrit ON Shapiro A Pode D . Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high

Full access

Peter E. Clark, Neeraj Agarwal, Matthew C. Biagioli, Mario A. Eisenberger, Richard E. Greenberg, Harry W. Herr, Brant A. Inman, Deborah A. Kuban, Timothy M. Kuzel, Subodh M. Lele, Jeff Michalski, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Jerome P. Richie, Wade J. Sexton, William U. Shipley, Eric J. Small, Philippe E. Spiess, Donald L. Trump, Geoffrey Wile, Timothy G. Wilson, Mary Dwyer and Maria Ho

Later studies had mixed results, with 2 reporting a decrease in recurrence and 1 finding no advantage. 13 – 15 The immediate intravesical chemotherapy may be followed by a 6-week induction of intravesical chemotherapy. Mitomycin C is the agent most

Full access

Richard S. Matulewicz, Brendan T. Frainey, Daniel T. Oberlin and Joshua J. Meeks

use of bladder-sparing procedures, such as transurethral resection of bladder tumor (TURBT) and adjuvant intravesical chemotherapy or immunotherapy. Clinical T1 high-grade (T1HG) bladder cancer is a potentially lethal subtype of NMIBC that may benefit